Alain Labelle, University of Ottawa

Research

Read how they describe their research on their University of Ottawa profile.

Latest papers

Safety of Adjunct Low-Dose Methylphenidate Extended-Release for Cognitive Deficits in Stable Schizophrenia: Results From an Open-Label, Randomized Crossover Trial.
Journal of clinical psychopharmacology · 2026
Efficacy of Low-Dose Adjunctive Methylphenidate Extended-Release on Cognition and Functioning in Individuals With Schizophrenia: A Randomized Open-Label Trial.
Journal of clinical psychopharmacology · 2026
Speech Mismatch Negativity (MMN) in Schizophrenia with Auditory Verbal Hallucinations.
Clinical EEG and neuroscience · 2025

All 29 publications

Latest funding

Is there an excess of haematological malignancies in people diagnosed with schizophrenia prescribed clozapine in Ontario: A planning grant to co-design a provincial study
CIHR · 2023 · Co-investigator
$10,000
A Proof-of-Concept Phase-I Trial of an Alpha7 Nicotinic Agonist for Cognitive Deficits in Schizophrenia
CIHR · 2013 · Co-investigator
$227,725

All 2 grants and awards

29 publications.

01

Safety of Adjunct Low-Dose Methylphenidate Extended-Release for Cognitive Deficits in Stable Schizophrenia: Results From an Open-Label, Randomized Crossover Trial.

Zhand N, Joober R, Labelle A, Iftikhar F, Robertson C, Harvey PD

Journal of clinical psychopharmacology2026

DOI: 10.1097/jcp.0000000000002220 PMID: 42305068

02

Efficacy of Low-Dose Adjunctive Methylphenidate Extended-Release on Cognition and Functioning in Individuals With Schizophrenia: A Randomized Open-Label Trial.

Zhand N, Joober R, Labelle A, Attwood D, Al Quraish F, Iftikhar F, Robertson C, Kozyra E, Carefoot E, Harvey PD

Journal of clinical psychopharmacology2026

DOI: 10.1097/jcp.0000000000002132 PMID: 41582768

03

Speech Mismatch Negativity (MMN) in Schizophrenia with Auditory Verbal Hallucinations.

Schryver B, Javier A, Choueiry J, Labelle A, Knott V, Jaworska N

Clinical EEG and neuroscience2025

DOI: 10.1177/15500594241292754 PMID: 39497433

04

Adjunctive methylphenidate extended release in patients with schizophrenia: Protocol of a single-centre fixed dose cross-over open-label trial to improve functional and cognitive outcomes.

Zhand N, Attwood D, Labelle A, Joober R, Robertson C, Harvey PD

Contemporary clinical trials communications2024

DOI: 10.1016/j.conctc.2024.101337 PMID: 39205914

05

An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.

Choueiry J, Blais CM, Shah D, Smith D, Fisher D, Labelle A, Knott V

Journal of psychopharmacology (Oxford, England)2023

DOI: 10.1177/02698811231158903 PMID: 36927273

06

Comparison of Extrapyramidal Symptoms Among Outpatients With Schizophrenia on Long-Acting Injectable Antipsychotics.

Zhand N, Labelle A, Ghanem D, Gujral P, Han T, Huneault G, Jain GK, Robertson C

Journal of clinical psychopharmacology2022

DOI: 10.1097/jcp.0000000000001580 PMID: 35977035

07

Alterations of Resting EEG in Hallucinating and Nonhallucinating Schizophrenia Patients.

Arora M, Knott VJ, Labelle A, Fisher DJ

Clinical EEG and neuroscience2021

DOI: 10.1177/1550059420965385 PMID: 33074718

08

Retrospective review of use of adjunctive psychostimulants in patients with schizophrenia.

Zhand N, Harvey P, Osborne R, Hatko A, Stuyt M, Labelle A

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists2021Senior author

DOI: 10.12788/acp.0015 PMID: 33529287

09

Interaction of Background Noise and Auditory Hallucinations on Phonemic Mismatch Negativity (MMN) and P3a Processing in Schizophrenia.

Francis AM, Knott VJ, Labelle A, Fisher DJ

Frontiers in psychiatry2020

DOI: 10.3389/fpsyt.2020.540738 PMID: 33093834

10

Change in the Neural Response to Auditory Deviance Following Cognitive Therapy for Hallucinations in Patients With Schizophrenia.

Knott V, Wright N, Shah D, Baddeley A, Bowers H, de la Salle S, Labelle A

Frontiers in psychiatry2020Senior author

DOI: 10.3389/fpsyt.2020.00555 PMID: 32595542

Is there an excess of haematological malignancies in people diagnosed with schizophrenia prescribed clozapine in Ontario: A planning grant to co-design a provincial study

Co-investigatorCIHR2023Planning and Dissemination Grant - Institute Community Support

Principal investigators: Zhand, Naista; Attwood, David

Keywords: Clozapine; Haematological Malignancies; Schizophrenia; Side Effects

$10,000

A Proof-of-Concept Phase-I Trial of an Alpha7 Nicotinic Agonist for Cognitive Deficits in Schizophrenia

Co-investigatorCIHR2013Operating Grant

Principal investigators: Knott, Verner J

Keywords: Alpha7 Nicotinic Receptor; Cognition; Event-Related Potentials; First Episode Schizophrenia; Schizophrenia; Sensory Gating

$227,725

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Psychiatry
Psychology
Psychiatry & Behavioural Neurosciences
Cellular and Molecular Medicine
Other

Co-authors at University of Ottawa, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.

Natalia Jaworska

Cellular and Molecular Medicine

1 shared papers, latest 2025

John Bradford

Psychiatry & Behavioural Neurosciences

1 shared papers, latest 2012

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mention

Subject: Prospective PhD student Dear Professor Labelle, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Safety of Adjunct Low-Dose Methylphenidate Extended-Release for Cognitive Deficits in Stable Schizophrenia: Results From an Open-Label, Randomized Crossover Trial." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Alain Labelle

Research

Latest papers

Latest funding

Safety of Adjunct Low-Dose Methylphenidate Extended-Release for Cognitive Deficits in Stable Schizophrenia: Results From an Open-Label, Randomized Crossover Trial.

Efficacy of Low-Dose Adjunctive Methylphenidate Extended-Release on Cognition and Functioning in Individuals With Schizophrenia: A Randomized Open-Label Trial.

Speech Mismatch Negativity (MMN) in Schizophrenia with Auditory Verbal Hallucinations.

Adjunctive methylphenidate extended release in patients with schizophrenia: Protocol of a single-centre fixed dose cross-over open-label trial to improve functional and cognitive outcomes.

An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.

Comparison of Extrapyramidal Symptoms Among Outpatients With Schizophrenia on Long-Acting Injectable Antipsychotics.

Alterations of Resting EEG in Hallucinating and Nonhallucinating Schizophrenia Patients.

Retrospective review of use of adjunctive psychostimulants in patients with schizophrenia.

Interaction of Background Noise and Auditory Hallucinations on Phonemic Mismatch Negativity (MMN) and P3a Processing in Schizophrenia.

Change in the Neural Response to Auditory Deviance Following Cognitive Therapy for Hallucinations in Patients With Schizophrenia.

Is there an excess of haematological malignancies in people diagnosed with schizophrenia prescribed clozapine in Ontario: A planning grant to co-design a provincial study

A Proof-of-Concept Phase-I Trial of an Alpha7 Nicotinic Agonist for Cognitive Deficits in Schizophrenia

Frequent collaborators

Verner Knott

Naista Zhand

Sara de la Salle

Dominique Bourget

Derek Fisher

David Attwood

Ridha Joober

Andra Smith

Robert Milin

Nicola Wright

Natalia Jaworska

Ridha Joober

John Bradford

Alain Labelle

Research

Latest papers

Latest funding

Safety of Adjunct Low-Dose Methylphenidate Extended-Release for Cognitive Deficits in Stable Schizophrenia: Results From an Open-Label, Randomized Crossover Trial.

Efficacy of Low-Dose Adjunctive Methylphenidate Extended-Release on Cognition and Functioning in Individuals With Schizophrenia: A Randomized Open-Label Trial.

Speech Mismatch Negativity (MMN) in Schizophrenia with Auditory Verbal Hallucinations.

Adjunctive methylphenidate extended release in patients with schizophrenia: Protocol of a single-centre fixed dose cross-over open-label trial to improve functional and cognitive outcomes.

An &#x3b1;7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.

Comparison of Extrapyramidal Symptoms Among Outpatients With Schizophrenia on Long-Acting Injectable Antipsychotics.

Alterations of Resting EEG in Hallucinating and Nonhallucinating Schizophrenia Patients.

Retrospective review of use of adjunctive psychostimulants in patients with schizophrenia.

Interaction of Background Noise and Auditory Hallucinations on Phonemic Mismatch Negativity (MMN) and P3a Processing in Schizophrenia.

Change in the Neural Response to Auditory Deviance Following Cognitive Therapy for Hallucinations in Patients With Schizophrenia.

Is there an excess of haematological malignancies in people diagnosed with schizophrenia prescribed clozapine in Ontario: A planning grant to co-design a provincial study

A Proof-of-Concept Phase-I Trial of an Alpha7 Nicotinic Agonist for Cognitive Deficits in Schizophrenia

Frequent collaborators

Verner Knott

Naista Zhand

Sara de la Salle

Dominique Bourget

Derek Fisher

David Attwood

Ridha Joober

Andra Smith

Robert Milin

Nicola Wright

Natalia Jaworska

Ridha Joober

John Bradford

An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.